Dr. Essam Hamza reports

TREATMENT.COM AI AND AIYIBOTONG COLLABORATE TO EXPLORE COMMERCIAL OPPORTUNITIES FOR CLINICAL DECISION SUPPORT IN CHINA AND FAR EAST

Treatment.com AI Inc. has recently signed a collaborative agreement on with Beijing Aiyi Botong Information Technology Ltd. (Aiyibotong). Each organization has a focus in providing enhanced clinical decision support for both health care professionals and patients, using innovative technologies including AI (artificial intelligence) and machine learning. Aiyibotong and Treatment are exploring complementary technology synergies, including Treatment's proprietary Global Library of Medicine (GLM), to enhance patient support in China and other Far East countries.

Investment in digital health in China is expected to reach $45-billion (U.S.) in 2025, including AI investment, driven by market expansion and strategic government investments. For example, according to Horizon Grand View Research, the clinical decision support (CDS) market in China alone is expected to double between 2024 and 2030, with a market size of approximately $600-million (U.S.) in 2030.

Treatment.com is partnering with Aiyibotong, a China-based health care information technology company focused on providing clinical decision supporting solutions (CDSSs) for medical professionals in both large hospitals as well as clinics. Its CDSSs have been developed on proprietary AI technologies, natural language processing (NLP), as well as machine learning algorithms and knowledge graph. Since its establishment in 2019, it has installed its CDSS systems in more than 200 health care institutions. The company is currently expanding its product portfolio to cover broader clinical quality assurance systems, including electronic medical record (EMR) quality assurance, venous thromboembolism (VTE) risk management and multidisciplinary team (MDT) assistants.

The envisaged areas of collaboration include:

• Aiyibotong assisting Treatment.com in localization of its Global Library of Medicine content and alignment with Chinese medical consensus;
• Aiyibotong licensing Treatment.com technology and integration with its CDSS platform;
• Co-marketing in China, targeting health care institutions and universities;
• Co-developing an AI-based CDSS for the global market, combining Aiyibotong's value of 10 years of experience in the sector and accumulated data and know-how, together with Treatment.com's technology and global medical professionals.

The agreement was signed on Feb. 19, 2025, and there are no costs associated with this agreement.

Treatment.com's Global Library of Medicine enables health care professionals to capture a patient's presenting symptoms, past medical history, and, through AI and smart proprietary algorithms, formulate the most likely diagnosis and suggest the most important tests/exams that should be performed. This history can then be shared with the patient's health care professional in real time and also programmed to help with triaging patients more efficiently.

The agreement was signed on Feb. 19, 2025, and there are no costs associated with this agreement. Treatment.com and Aiyibotong have already started to explore mutually beneficial opportunities through China and the Far East regions.

Dr. Essam Hamza, chief executive officer of Treatment.com AI, commented: "We look forward to working with Aiybotong to expand the GLM to new languages and opportunities in Asia and the Far East. Amongst the solutions, we believe can augment Aiyibotong's product lines, our new AI voice agent/assistant speaking in regional languages and, with local dialects, can help onboard and triage marginalized and underserved patients in the community."

Chenjin Liu, general manager of Aiyibotong, commented: "Aiyibotong is in the process of adopting new LLM [large language model] technologies in our CDSS product lines and will use the knowledge-plus-data hybrid model to drive our system so that the LLM can make our product more AI empowered while our existing knowledge graph and expert system will effectively limit the hallucination in LLM. We're excited to collaborate with Treatment as their Global Library of Medicine can be a great value add to enhance our expert system. In addition to the China market, we see this hybrid-model-driven CDSS can be a global product."

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the health care sector and impact current inefficiencies and challenges. With the input of hundreds of health care professionals globally, Treatment.com AI has built a comprehensive, personalized health care AI engine -- the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all health care professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps health care professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI's GLM platform, through supporting health care professionals, allows for the inclusion of disenfranchised communities.

We seek Safe Harbor.